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Abstract
 
Transforming growth factor (TGF)-
 
b
 
1 
 
is a pleiotropic cytokine/growth factor that is thought to
play a critical role in the modulation of inflammatory events. We demonstrate that exogenous
TGF-
 
b
 
1 
 
can inhibit the expression of the proinflammatory adhesion molecule, E-selectin, in
vascular endothelium exposed to inflammatory stimuli both in vitro and in vivo. This inhibi-
tory effect occurs at the level of transcription of the E-selectin gene and is dependent on the ac-
tion of Smad proteins, a class of intracellular signaling proteins involved in mediating the cellu-
lar effects of TGF-
 
b
 
1
 
. Furthermore, we demonstrate that these Smad-mediated effects in
endothelial cells result from a novel competitive interaction between Smad proteins activated
by TGF-
 
b
 
1 
 
and nuclear factor 
 
k
 
B (NF
 
k
 
B) proteins activated by inflammatory stimuli (such as
cytokines or bacterial lipopolysaccharide) that is mediated by the transcriptional coactivator cy-
clic AMP response element–binding protein (CREB)-binding protein (CBP). Augmentation of
the limited amount of CBP present in endothelial cells (via overexpression) or selective disrup-
tion of Smad–CBP interactions (via a dominant negative strategy) effectively antagonizes the
ability of TGF-
 
b
 
1 
 
to block proinflammatory E-selectin expression. These data thus demonstrate
a novel mechanism of interaction between TGF-
 
b
 
1
 
–regulated Smad proteins and NF
 
k
 
B pro-
teins regulated by inflammatory stimuli in vascular endothelial cells. This type of signaling
mechanism may play an important role in the immunomodulatory actions of this cytokine/
growth factor in the cardiovascular system.
Key words: inﬂammation • transcription • transforming growth factor • vascular biology • 
endothelium
 
Introduction
 
As the requisite interface between blood and all tissues of
the body, vascular endothelium plays an integral role in the
process of inflammation. Rather than being simply a pas-
sive barrier, it is now clear that this cell type can integrate
both blood-borne and tissue-derived signals, and thus
function to actively mediate the recruitment of leukocytes
to areas of inflammation. A critical event in this process is
the regulated endothelial expression of cell surface adhe-
sion molecules such as E-selectin. This protein, which was
originally identified as a cytokine-inducible cell surface
protein in cultured endothelial cells, has been shown to
play an important role in mediating early leukocyte–endo-
thelial interactions such as initial attachment and rolling
(1). Thus, the regulated expression of this and other adhe-
sion molecules in vascular endothelium has been an active
area of investigation (2). E-selectin expression is regulated
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primarily at the level of transcriptional activation, a process
that is mediated by a series of tandem nuclear factor 
 
k
 
B
(NF
 
k
 
B)
 
1
 
 sites in the promoter of this gene. Stimuli such as
IL-1
 
b
 
 and TNF-
 
a
 
 can rapidly induce the expression of the
E-selectin gene in endothelial cells by activating NF
 
k
 
B
and stimulating the transcription of the E-selectin pro-
moter (2–5).
The TGF-
 
b
 
 superfamily constitutes a large and diverse
family of protein cytokines/growth factors that play impor-
tant roles in processes ranging from differentiation and de-
velopment to the regulation of cell growth and extracellu-
lar matrix biology (6, 7). One of the areas in which TGF-
 
b
 
1
 
(the prototypic member of this family) is thought to play an
especially critical role is the modulation of inflammatory
responses. TGF-
 
b
 
1 
 
is a powerful and essential immune
modulator in the vascular system, where it participates in
the regulation of inflammatory events in both leukocytes
and vascular endothelial cells (8). This is most dramatically
illustrated by the phenotype of mice that lack the gene for
the TGF-
 
b
 
1
 
 isoform. These mice die in utero or in the
perinatal period because of widespread, uncontrolled in-
flammation, and this pathological phenotype can be re-
versed by the systemic administration of active soluble
TGF-
 
b
 
1 
 
(9). Previous work has demonstrated that TGF-
 
b
 
1
 
can inhibit cytokine-induced E-selectin expression in cul-
tured endothelial cells (a cardinal sign of endothelial activa-
tion in the context of inflammation), suggesting that the
endothelium may be an important target for the antiinflam-
matory actions of TGF-
 
b
 
1 
 
(10).
Over the last several years, the general intracellular sig-
naling mechanisms used by the TGF-
 
b
 
 
 
superfamily have
begun to be elucidated (6, 7, 11). In the case of TGF-
 
b
 
1
 
, its
cellular effects appear to be transduced via at least three
types of cell surface receptors (types I, II, III), two of which
are serine/threonine kinases. The active form of soluble
TGF-
 
b
 
1
 
 binds to the type II receptor at the cell surface, and
this complex subsequently interacts with and transphos-
phorylates the cytoplasmic domain of the type I receptor.
This phosphorylation event activates the type I receptor ki-
nase domain, which then propagates downstream signals
within the cell. Smad proteins (known previously as MAD-
related proteins for mothers against decapentaplegic) are es-
sential components in the signaling pathways of the TGF-
 
b
 
1
 
type I serine/threonine kinase receptors (12). Smads func-
tion as intracellular signaling intermediates by specifically
interacting with ligand-activated receptor complexes at the
cell surface and subsequently translocating to the nucleus,
where they modulate gene expression (a general mecha-
nism of action that is thought to be similar to that of the
signal transducer and activator of transcription [STAT]
family of signaling molecules). We and others have demon-
strated that Smad proteins interact functionally with the
transcriptional coactivators CREB-binding protein (CBP)/
P300, a process that is essential to their ability to function as
transcriptional effectors (13–17).
In this report, we demonstrate that the ability of TGF-
 
b
 
1
 
to antagonize cytokine-induced E-selectin expression in
vascular endothelium is Smad protein dependent and in-
volves a novel “competitive” interaction between Smad
proteins and NF
 
k
 
B that is mediated by the transcriptional
coactivator CBP. These data thus indicate a new mecha-
nism by which this important class of cytokines/growth
factors can interact with and modulate a signal transduction
pathway mediating inflammatory events.
 
Materials and Methods
 
Reagents, Cell Culture, Transfections, and Reporter Assays.
 
Hu-
man umbilical vein endothelial cells (HUVECs) were isolated
from multiple segments of normal term umbilical cords, pooled,
and cultured in Medium 199 (GIBCO BRL) supplemented with
Endothelial Cell Growth Supplement (50 
 
m
 
g/ml; Collaborative
Research, Inc.), heparin (50 
 
m
 
g/ml, porcine intestinal; Sigma-
Aldrich), antibiotics (penicillin-G, 100 U/ml and streptomycin, 100
 
m
 
g/ml; Sigma-Aldrich), and 20% fetal bovine serum. Primary bo-
vine aortic endothelial cells (BAECs) were isolated and cultured as
described (18). These were used at passages 3–9. Transient trans-
fections were performed on subconfluent (70%) monolayers of
endothelial cells by coincubating the cells with DNA and lipo-
fectamine (GIBCO BRL) for 6 h according to manufacturer’s in-
structions. The DNA/lipofectamine mixture was then removed
and replaced with media containing serum. In all cases, the
monolayers were allowed to reach confluence for 24–48 h after
transfection before subsequent treatment or analysis. A plasmid
encoding the cytomegalovirus promoter driving expression of the
 
b
 
-galactosidase gene (CMV-
 
b
 
 gal) was routinely cotransfected to
control for transfection efficiency and normalize for yield, and in-
dividual conditions were performed in duplicate. When multiple
plasmids were cotransfected (e.g., reporter and expression plas-
mids), the total amount of DNA was kept constant by augment-
ing samples with empty expression vectors. Both luciferase and
 
b
 
-galactosidase activity were measured in the same sample using the
Dual-Light system (Tropix). For the transfection experiments, the
results shown are reported as ratios of luciferase to 
 
b
 
-galactosidase
activity and are representative of at least three independent exper-
iments. The error bars displayed represent 
 
6
 
 1 SD of the mean.
The Smad protein expression constructs are all present in pCi-
neo (Promega) and encode epitope-tagged versions of the Smad
proteins (hemagglutinin or Flag) or are fused in frame to the Gal4
DNA binding domain, and have been described previously (13,
19). Smad2
 
*
 
P is a form of Smad2 that has had its COOH-termi-
nal SSXS motif deleted, and Smad4d514 is a truncated form of
Smad4 that terminates at amino acid 514. The expression of
these proteins in transfection experiments was monitored by West-
ern analyses to maintain equal levels between constructs. The
E-selectin promoter was provided by T. Collins (Brigham and
Women’s Hospital, Boston, MA), and the CBP expression con-
struct was provided by S. Bhattacharya (Dana-Farber Cancer In-
stitute, Boston, MA). The simplified NF
 
k
 
B promoter and the
Gal4-Jun fusion constructs were obtained from CLONTECH
Laboratories, Inc. The constructs expressing the subdomains of
CBP were created by PCR and incorporated a Flag epitope tag at
their NH
 
2
 
 terminus, and were cloned into pCi-neo (Promega).
All constructs have been sequenced. Active TGF-
 
b
 
1
 
 was ob-
tained from R&D Systems.
 
1
 
Abbreviations used in this paper: 
 
BAEC, bovine aortic endothelial cell;
CBP, cyclic AMP response element–binding protein (CREB)-binding
protein; HUVEC, human umbilical vein endothelial cell; NF
 
k
 
B, nuclear
factor 
 
k
 
B. 
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Mobility Shift, Western, and Fluorescence Immunoassay Analyses.
 
Western blots for Smad2, p65, CBP, and the epitope tags (Flag,
hemagglutinin, myc) were performed with antisera obtained
commercially from Santa Cruz Biotechnology, Inc., Zymed Lab-
oratories, BD PharMingen, and R&D Systems. After separation
of proteins on SDS-PAGE gels, they were transferred to nitrocel-
lulose by electroblot and the membranes were incubated with the
appropriate antisera. Proteins were detected with the use of
horseradish peroxidase–linked secondary antisera and chemilumi-
nescence. Nuclear extracts prepared from HUVEC monolayers
were used for the mobility shift analyses and prepared as de-
scribed (3). The sequences of the double-stranded oligonu-
cleotide probe used was 5
 
9
 
-GCCATTGGGGATTTCCTCTT-
TACTGGATGT-3
 
9
 
. The specificity of the gel shifts was
confirmed by immunodepleting these extracts with the anti-p65
antisera before mobility shift analysis. This was accomplished by
incubating the extracts with the appropriate antisera (or nonim-
mune IgG as the control) overnight at 4
 
8
 
C, then capturing the
antibodies with the appropriate antiisoform-coupled beads for 30
min and removing them by centrifugation. Fluorescence immu-
noassays for cell surface E-selectin were performed by fixing the
endothelial monolayers with 2% paraformaldehyde for 2 min,
then incubating the monolayers with an antisera that reacts with
cell surface E-selectin, as described previously (1). After washing,
the monolayers are incubated with a secondary antibody coupled
to FITC, then washed and lysed, and the fluorescence was read in
a plate reader. This assay is a highly quantitative and reproducible
assessment of the level of cell surface E-selectin expression.
 
In Vivo Experiments.
 
LPS (
 
Salmonella typhi
 
; Sigma-Aldrich)
was administered to experimental rats at 4 mg/kg intraperito-
neally, and 6 h later the hearts, lungs, and liver of these animals
were harvested, washed in sterile cold PBS, and frozen in liquid
nitrogen. For the pretreatment experiments, animals received ei-
ther vehicle or 20 
 
m
 
g/kg active TGF-
 
b
 
1
 
 30 min before LPS chal-
lenge. Total RNA was prepared from tissues by rapid homogeni-
zation in lysis solution and extraction (Ambion), and was
separated on formaldehyde gels and blotted to nylon for North-
ern analysis. Extracts of tissues for mobility shift analyses or West-
ern analyses were performed essentially as described (3). In brief,
the tissues were ground up under liquid nitrogen, and proteins
were extracted in buffer containing 20 mM Hepes, pH 7.4,
10mM KCl, 400 mM NaCl, 0.15 mM EDTA, 1 mM dithiothre-
itol, and protease and phosphatase inhibitors. 
 
z
 
2–5 
 
m
 
g of protein
extract was used per mobility shift reaction. For the Western
analysis, the ground tissues were immediately extracted with
buffer containing 1% SDS, 50 mM Tris, pH 7.5, 50mM NaCl, 1
mM EDTA, and protease and phosphatase inhibitors. These ex-
tracts were then analyzed as described above.
 
Results
 
TGF-
 
b
 
 Can Inhibit Inflammatory Cytokine-induced Adhesion
Molecule Expression in Endothelial Cells by Transcriptional
Mechanism(s) Involving NF
 
k
 
B.
 
Exogenous TGF-
 
b
 
1
 
 has
been reported to inhibit the expression of a variety of in-
flammatory genes in vascular endothelial cells. One such
gene is E-selectin, an inducible cell surface adhesion mole-
cule selectively expressed in vascular endothelium. We
chose to examine the cytokine-induced expression of this
gene in the presence or absence of pretreatment with solu-
ble active TGF-
 
b
 
1
 
. As demonstrated by a fluorescence im-
munoassay (Fig. 1 A), E-selectin protein is rapidly induced
on the surface of cultured HUVECs by both 5 and 10 U/ml
of recombinant human IL-1
 
b
 
. However, when the cells
are preincubated in the presence of TGF-
 
b
 
1
 
, this induction
can be markedly attenuated. This effect could be seen with
a little as 30 min of pretreatment with TGF-
 
b
 
 (data not
shown). The dose response for the inhibitory effect of ex-
ogenous TGF-
 
b
 
1 
 
demonstrated a U-shaped curve whereby
intermediate doses of TGF-
 
b
 
1
 
 (0.1–1 ng/ml of active TGF-
 
b
 
1
 
) were maximally effective, whereas higher doses (5–10
ng/ml) were significantly less effective (Fig. 1 A; data not
shown). The data displayed in Fig. 1 consist of representa-
tive data using low-passage HUVECs at confluence and 6 h
of TGF-
 
b
 
1 
 
prestimulation followed by 4 h of rhIL-1
 
b
 
 stim-
ulation. These results confirm the findings of several other
investigators, demonstrating that TGF-
 
b
 
1 
 
can effectively in-
hibit endothelial adhesion molecule expression in vitro (10).
Figure 1. (A) Inducible expression of E-selectin protein on the surface
of cultured endothelial cells in response to Il-1b can be inhibited by pre-
treatment with active TGF-b1. The level of cell surface E-selectin protein
was determined by fluorescence immunoassay at baseline and 4 h after
treatment with 5 or 10 U/ml of rhIL-1b (left). To assess the effect of
TGF-b1 pretreatment, the cells were exposed to the indicated doses of ac-
tive TGF-b1 for 6 h before cytokine treatment. The right panel demon-
strates that pretreatment of HUVECs with intermediate doses of TGF-b1
markedly diminished cytokine-induced E-selectin expression. (B) Pre-
treatment of TGF-b can inhibit cytokine-induced transcription of the
E-selectin promoter and a simplified NFkB-dependent promoter in endo-
thelial cells. Luciferase reporter constructs containing either the E-selectin
promoter (left and middle) or a promoter consisting of a series of tandem
NFkB sites (right) were transiently transfected into HUVECs. The cells
were subsequently stimulated with rhIL-1b for 4 h, and luciferase levels
were measured and normalized to b-galactosidase activity (from a
cotransfected CMV-b gal reporter vector). As shown in the left panel,
both 5 and 10 U/ml of rhIL-1b effectively induce transcription from the
E-selectin promoter. In the middle and right panels, the cells were pre-
treated with the indicated doses of active TGF-b 1 for 6 h before cytokine
stimulation (5 U/ml). Intermediate doses of TGF-b1 were effective at in-
hibiting cytokine-induced, NFkB-mediated transcription. 
698 Integration of TGF-b and Inflammatory Signaling via CBP in Endothelium
The inducible expression of E-selectin in endothelial
cells is primarily regulated at the level of transcriptional ac-
tivation. To examine whether the ability of TGF-b1 to in-
hibit cell surface protein expression resulted from a down-
regulation of transcriptional activation of the E-selectin
gene, we used an E-selectin promoter construct in transient
transfection assays. As shown in Fig. 1 B, this construct is
significantly induced in the presence of rhIL-1b (as well as
TNF-a; data not shown), and preincubation of the trans-
fected cells with TGF-b1 before inflammatory cytokine
stimulation resulted in a significant attenuation of the in-
duction of this promoter. The dose response of TGF-b1 for
this effect was identical to that observed for E-selectin pro-
tein induction, suggesting that the inhibitory mechanism
involves a modulation of transcriptional events. The E-selec-
tin promoter is known to be regulated by cis-acting
NFkB sites. Thus, we examined whether a simplified pro-
moter construct consisting of tandem NFkB sites would
demonstrate a similar response. As shown in Fig. 1 B, the
induction of this promoter by rhIL-1b in transfected en-
dothelial cells was also significantly inhibited by pretreat-
ment with TGF-b1. We found essentially identical results if
we used TNF-a as the inflammatory stimulus or if we used
primary cultures of BAECs that are more readily transfect-
able than HUVECs, and thus less subject to artifacts result-
ing from low transfection efficiencies (data not shown).
Taken together, these results indicate that TGF-b1 is capa-
ble of modulating the transcriptional induction of the E-selec-
tin gene through an NFkB-dependent mechanism.
TGF-b–mediated Inhibition of Inducible E-Selectin Expres-
sion Is Smad Protein Dependent. Smad proteins are a re-
cently identified class of intracellular proteins that have
been demonstrated to play essential roles in TGF-b1 super-
family–mediated signal transduction and gene expression
(6, 7, 11). These proteins fall into three general classes. The
so-called receptor-activated (or signaling) Smads (Smad2
and Smad3 in the case of TGF-b1) are direct cytoplasmic
substrates for the serine/threonine kinase present in acti-
vated TGF-b superfamily type 1 receptors. Once phosphor-
ylated by the receptor, these proteins complex with a dis-
tinct class of Smad, Smad4, which is not a substrate for the
receptor but is required for maximal signaling. This com-
plex then translocates to the nucleus and modulates the ex-
pression of a variety of genes. A third class of Smad pro-
teins, termed the inhibitory Smads, Smad6 and Smad7, can
inhibit specific steps in this signaling cascade by either in-
teracting with the activated type 1 receptor and blocking its
ability to phosphorylate signaling Smads such as Smad2 or
Smad3, or by interfering with required Smad–Smad inter-
actions (18, 20, 21).
To determine if the inhibitory effects of TGF-b1 on in-
ducible E-selectin gene expression in endothelial cells were
Smad dependent, we transfected BAECs with several Smad
protein expression constructs and examined the response of
Figure 2. (A) TGF-b1–mediated inhibition of IL-1b–induced E-selectin expression in endothelial cells is Smad protein dependent. BAECs were tran-
siently cotransfected with the E-selectin promoter construct and the indicated Smad protein expression constructs or an empty expression vector (pCi).
The cells were subsequently stimulated for 4 h with TNF-a, with and without 6 h of pretreatment with TGF-b1 at 1 ng/ml. The level of induction of
the E-selectin promoter has been normalized to that seen in the absence of TGF-b1 pretreatment (in the presence of the cotransfected empty expression
vector) and expressed as 100%. In the presence of cotransfected empty expression vector (pCI), there is a marked inhibition of E-selectin promoter induc-
tion by TGF-b1 pretreatment, as described in the legend to Fig. 1. Coexpression of Smad7, an inhibitory Smad protein, or of Smad2*P or Smad4 (d514),
which can act as dominant negative inhibitors, markedly attenuates the TGF-b1–mediated inhibition. In contrast, coexpression of wild-type Smad2,
Smad4, or both Smad2 and -4 significantly enhances the level of inhibition seen and is able to induce varying levels of inhibition even in the absence of
exogenous TGF-b1 pretreatment. All of the Smad expression constructs encode epitope-tagged species that were expressed at comparable levels as moni-
tored by immunoblot (data not shown). (B) Cytokine-induced activation of NFkB appears preserved in the presence of TGF-b1 pretreatment. HUVEC
monolayers were treated with 10 U/ml of rhIL-1b for 30 min and lysed, and a nuclear extract was prepared. Specific NFkB-mediated DNA binding ac-
tivity was assessed by mobility shift assay and compared with that present in unstimulated HUVEC. As shown in the left panel, there is a specific shifted
band present in the rhIL-1b–treated lanes but not in the control (untreated) lane that can be abolished by immunodepletion of the extract with a mixture
of anti-p65/antip50 antisera but not nonspecific IgG. As shown in the middle panel, rhIL-1b–induced, NFkB-mediated DNA binding activity (as as-
sessed by this gel shift) appears preserved even in the presence of TGF-b pretreatment. The panels at the right represent immunoblots for IkB and P65
protein levels. The former is markedly depleted by rhIL-1b treatment, even in the presence of TGF-b1 pretreatment. p65 levels appeared stable under
these conditions. These findings suggest that IkB degradation and NFkB-mediated DNA binding are not affected by TGF-b1 pretreatment in HUVECs.699 DiChiara et al.
a cotransfected E-selectin promoter construct to exogenous
TNF-a (both with and without TGF-b pretreatment). As
shown in Fig. 2 A, TGF-b1 at 1 ng/ml resulted in a signifi-
cant inhibition of promoter induction in the presence of a
cotransfected empty expression plasmid (pCi), but in the
presence of the expression plasmid encoding the inhibitory
Smad, Smad7, this TGF-b1–mediated inhibition was com-
pletely abolished. Conversely, when Smad2, Smad4, or
both Smad2 and Smad4 were overexpressed, there was a
reduction in the TNF-a–induced level of E-selectin pro-
moter activity even in the absence of TGF-b1 pretreat-
ment, as well as a significant enhancement of the inhibitory
effect of exogenous TGF-b1 (Fig. 2 A). We used two addi-
tional constructs: pSmad2*P, which expresses a form of
Smad2 that is not a substrate for the activated TGF-b1 type
1 receptor, and a COOH-truncated form of Smad4
(pSmad4d514) that is inactive as a transcriptional activator.
When overexpressed, both of these proteins can act as
dominant negative regulators of Smad signaling. These
constructs significantly ameliorated the ability of TGF-b1
to inhibit inflammatory cytokine–induced E-selectin ex-
pression (Fig. 2 A). Taken together, these results indicate
that the inhibitory effects of TGF-b1 on inducible E-selec-
tin expression in endothelial cells are Smad protein depen-
dent and can be mimicked by overexpression of Smad2 and
-4 and blocked by the inhibitory Smad7.
The activation of NFkB by inflammatory stimuli in en-
dothelial cells involves a series of events culminating in the
phosphorylation and degradation of the inhibitory protein
IkB and subsequent nuclear localization and DNA binding
of p50/p65 heterodimers to specific DNA sequences (2).
To examine the effects of TGF-b1 on these events in en-
dothelial cells, we stimulated confluent HUVECs with
rhIL-1b in the presence or absence of TGF-b1 pretreat-
ment, and examined NFkB DNA binding by gel shift anal-
ysis and levels of immunoreactive p65 and IKBa by West-
ern blotting. As demonstrated in Fig. 2 B, in extracts of
control (unstimulated) HUVECs, there is essentially no de-
tectable gel shift of an NFkB-specific probe. After stimula-
tion with IL-1b, a discrete gel-shifted band is detected.
The specificity of this band was confirmed by immunode-
pleting the extract with an anti-p65 antisera, which elimi-
nated this gel shift. Interestingly, when this analysis was
performed on HUVECs that had been preincubated with
TGF-b1, there was no detectable difference in NFkB acti-
vation as assessed by this gel shift assay (Fig. 2 B). At all
doses of TGF-b1 pretreatment, rhIL-1b treatment resulted
in the induction of a detectable NFkB-mediated gel shift.
When we examined the levels of NFkB proteins by immu-
noblot, the levels of immunoreactive IkBa were markedly
diminished by rhIL-1b treatment, whereas the levels of p65
were not significantly altered whether or not the cells were
pretreated with TGF-b1 (Fig. 2 B). These results indicate
that under conditions where TGF-b1 can significantly in-
hibit NFkB-mediated E-selectin expression, activation of
NFkB appears to be preserved, and suggest that a step sub-
sequent to NFkB-mediated DNA binding is the site of
TGF-b/Smad-mediated inhibition.
TGF-b Can Inhibit Inducible E-Selectin Expression In Vivo.
To determine whether the results in cultured endothelial
cells described above could be reproduced in an in vivo
model, we examined the ability of systemic TGF-b1 to
inhibit LPS-induced E-selectin expression in rats. Previ-
ous work has demonstrated the ability of systemically ad-
ministered TGF-b1 to inhibit the expression of several in-
flammatory genes, such as inducible nitric oxide synthase II
and heme oxygenase, and to ameliorate the course of LPS-
induced shock, although the precise mechanism(s) of these
effects have not been elucidated (22–24). We initially ex-
amined the ability of LPS to induce E-selectin mRNA ex-
pression in whole organs in vivo. As demonstrated in Fig. 3
A, E-selectin mRNA was not detected in total RNA (15
mg) from the lung, liver, and heart of control rats but is
readily detected after 6 h of LPS administration. Given that
E-selectin is selectively expressed in vascular endothelium,
the varying amounts of E-selectin mRNA detected (in a
constant amount of total RNA) probably reflect both the
degree to which endothelium contributes the overall RNA
content of the individual tissues, and differences in the de-
gree to which E-selectin expression is induced by LPS in
these distinct tissue environments. To examine the effects
of TGF-b1, a second set of rats received either vehicle or
20 mg/kg of active TGF-b1 intraperitoneally, followed 20
min later by 4 mg/kg of LPS. The lungs, heart, and liver of
these animals were harvested 6 h later for RNA and pro-
tein analysis. As demonstrated in Fig. 3 A (right), TGF-b1
pretreatment markedly attenuated the level of E-selectin
mRNA induced in all three tissues. To examine whether
NFkB was being activated to similar extents, we next ex-
amined the DNA binding activity of protein lysates from
rat tissues. As demonstrated in Fig. 3 B (left), lysates from
LPS-treated rat lung tissue demonstrate a gel-shifted band
that is not seen in lysates from control lungs and that can be
abolished by immunodepletion with an ap65/p50 antisera.
When these analyses were performed on lysates from tissues
derived from the LPS-treated rats, no detectable difference
in NFkB-mediated DNA binding was seen between the
sham and TGF-b1–pretreated animals (Fig. 3 B). Fig. 3 C
demonstrates that the levels of immunoreactive p65 appear
to be equal among the groups and that the levels of IkBa
are slightly diminished in the absence of TGF-b1 pretreat-
ment, but not abolished. Taken together, these results indi-
cate that LPS can effectively upregulate E-selectin expres-
sion in vivo, and that this effect can be significantly
attenuated by systemic pretreatment with TGF-b1. Fur-
thermore, this inhibition can occur in the absence of a de-
tectable decrement in the levels of immunoreactive NFkB
or the degree to which NFkB is activated as assessed by
specific DNA binding assay.
TGF-b Inhibition of E-Selectin Expression Is Mediated by
Smad–Coactivator (CBP) Interactions. Transcriptional coac-
tivators are a class of proteins that participate in transcrip-
tional regulation by directly interacting with cis-acting
transcriptional activators, components of the basal tran-
scriptional apparatus, and chromatin (25–27). One member
of this class of molecules, CBP, is capable of interacting700 Integration of TGF-b and Inflammatory Signaling via CBP in Endothelium
with many regulated transcriptional effectors, and these in-
teractions have been postulated as important loci of signal
integration (28–30). Both NFkB and Smad proteins have
been demonstrated to interact with CBP, an event that is
required for transcriptional activation by these proteins in
endothelial cells (13, 31). To examine these interactions di-
rectly, we subjected lysates from control, rhIL-1b–treated,
or TGF-b1–pretreated/rhIL-1b–treated HUVEC mono-
layers to immunoprecipitation with antisera against Smad2,
p65, and CBP and probed the immunoprecipitates for asso-
ciated proteins by immunoblot. As shown in Fig. 4 A, im-
munoprecipitations with anti-Smad2 antisera effectively
brought down Smad2 protein under all conditions, but
only brought down CBP after the cells were treated with
TGF-b1, and did not bring down detectable amounts of
p65 under any conditions examined. These results are con-
sistent with previous data demonstrating that Smad–CBP
interactions are ligand (TGF-b1) dependent (13), and fur-
ther indicate that p65 and Smad2 do not appear to be
present in the same transcriptional complexes in these cells.
When these lysates were immunoprecipitated with anti-p65
antisera, CBP only coprecipitated after rhIL-1b treatment.
Interestingly, if the cells were pretreated with TGF-b1 be-
fore rhIL-1b, then CBP was not found in p65-containing
complexes. These results suggest that in the presence of
TGF-b1 pretreatment, Smad proteins are able to effectively
recruit CBP, whereas p65 is not. These results were con-
firmed by immunoprecipitating with anti-CBP. This
brought down p65 in the rhIL-1b–treated cells; however,
in the TGF-b1 pretreated cells, immunoprecipitation with
anti-CBP brought down Smad2 but not p65. These results
suggest that there is a competition between activated Smads
and activated p65 for what may be effectively limiting
amounts of CBP in the nuclei of endothelial cells. To ex-
amine this hypothesis directly, we overexpressed the full-
length CBP protein in BAECs and examined the effects on
the ability of TGF-b1 to inhibit NFkB-mediated gene ex-
pression. As demonstrated in Fig. 4 B, overexpression of
CBP augmented the expression of the NFkB-dependent
reporter under all conditions to a modest degree, but com-
pletely abolished the ability of TGF-b1 pretreatment to in-
hibit the TNF-a–induced induction of this promoter. The
ability of overexpressed CBP to abolish the inhibitory ac-
tions of TGF-b1 appeared dose dependent. As shown in
Fig. 4 B (right), increasing ratios of cotransfected CBP ex-
pression plasmid resulted in decreasing degrees of inhibi-
tion in response to TGF-b1 pretreatment. This effect was
not seen with a truncated form of CBP that is not capable
of interacting with Smad proteins (data not shown).
To demonstrate that the ability of CBP to reverse TGF-
b/Smad-mediated inhibition of NFkB-mediated gene ex-
pression was not due to nonspecific induction of general
transcription by overexpressed CBP, we employed a domi-
nant negative approach to selectively interfere with Smad–
Figure 3. (A) Induction of E-selectin
mRNA in rat tissues by LPS can be inhib-
ited by systemic pretreatment with TGF-b1.
As described in Materials and Methods, rats
received 4 mg/kg of LPS intraperitoneally,
and 6 h later the indicated tissues were har-
vested and processed for RNA and protein
extracts as described. (A) As shown by
Northern analysis (left panel), E-selectin
mRNA is not detected in control tissues but
is detectable in the lung, liver, and hearts 6 h
after LPS administration. In the right panels,
tissues from LPS-treated animals that had
received either vehicle or TGF-b1 pretreat-
ment were similarly analyzed. Each pair of
lanes represents two independently treated
animals. Pretreatment with TGF-b1 mark-
edly attenuated E-selectin mRNA induc-
tion (upper blots) but did not affect glycer-
aldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA levels (lower blots). (B)
NFkB-mediated DNA binding activity ap-
pears preserved after TGF-b1 pretreatment
in vivo. The lungs and hearts of LPS-treated
rats were processed to obtain nuclear ex-
tracts for DNA mobility shift analyses with
the NFkB-specific oligo probes as described
in the legend to Fig. 2. In the left panel, a
specific shifted band is detected in lysates
from LPS-treated rat lung that is not present in lysates from control lung and that is attenuated by immunodepletion with antip65/p50 antisera but not
nonimmune IgG. The middle and right panels are lysates from lung and heart, respectively, from the animals that have received LPS with or without
TGF-b1 pretreatment. Each pair of lanes represents two independently treated animals. TGF-b1 pretreatment in vivo does not appear to affect LPS-
induced NFkB-mediated DNA binding in these tissues. (C) Western analysis for p65 and IkB levels in tissues from LPS and TGF-b1–pretreated rats.
The levels of immunoreactive p65 and IkB in the rat tissues were assessed by immunoblot. Each pair of lanes represents two independently treated ani-
mals. Levels of p65 were not significantly altered in response to any of the treatment protocols. The levels of immunoreactive IkB appeared slightly de-
pressed by LPS treatment in the absence of TGF-b1 pretreatment.701 DiChiara et al.
CBP interactions. Using a mammalian two-hybrid strategy,
we have mapped the domain of the large CBP protein that
interacts with Smad2 in endothelial cells (13) to amino ac-
ids 1892–2175 (schematized in Fig. 4 C). We then created
vectors to express this domain of CBP (termed 1892) as
well as an adjacent domain of CBP corresponding to amino
acids 1459–1891 (termed 1459) as epitope-tagged species.
The effects of overexpression of these proteins on gene ex-
pression in endothelial cells was then examined. As demon-
strated in Fig. 4 D, overexpression of 1892 markedly inhib-
ited the TGF-b1–mediated induction of p3Tp-lux, a
chimeric TGF-b1 responsive promoter, whereas 1459 had
no effect. Similarly, the 1892 protein markedly inhibited
the transcriptional activity of a Gal4-Smad2 fusion protein
in response to TGF-b1, whereas 1459 had no effect. In
contrast, neither protein inhibited the transcriptional activ-
ity of a Gal4-Jun fusion protein (stimulated by forced ex-
pression of a constitutively active form of the kinase mito-
gen-activated protein kinase kinase 1 (MEKK-1). These
results indicate that overexpression of the 1892–2441 sub-
domain of CBP can effectively act as a selective inhibitor of
TGF-b1–mediated, Smad-2–dependent transcriptional ac-
tivation in endothelial cells (presumably via a dominant
negative mechanism), whereas the 1459–1891 subdomain
cannot. We next examined the effects of overexpression of
these proteins on the ability of TGF-b1 to inhibit cytokine-
induced NFkB-mediated gene expression. As shown in
Fig. 4 E, in the presence of overexpressed 1459, pretreat-
ment of the endothelial cells with TGF-b1 was still able to
inhibit TNF-a–induced reporter gene expression, whereas
Figure 4. (A) Smad2 but not p65 is recruited into a CBP-containing complex in response to TGF-b1 pretreatment followed by rhIL-1b treatment of
HUVECs. HUVEC monolayers were treated with 10 U/ml of rhIL-1b for 30 min with and without pretreatment with TGF-b1 at 1 ng/ml for 6 h. Pro-
tein lysates were then prepared and immunoprecipitated with anti-Smad2, anti-p65, or anti-CBP antisera as indicated. These immunoprecipitates were
then analyzed by Western blot with the antisera indicated. (B) Overexpression of CBP reverses TGF-b1–mediated inhibition of TNF-a–induced NFkB-
mediated transcription. BAEC monolayers were cotransfected with the simplified NFkB-dependent promoter and either empty expression vector or
vector encoding wild-type CBP (left). They were then treated with TNF-a (100 U/ml) both with and without TGF-b1 pretreatment (1 ng/ml), as de-
scribed, and luciferase activity was assayed 12 h later. Overexpression of CBP reversed the ability of TGF-b1 pretreatment to inhibit NFkB-mediated
transcription. The right panel shows cells that were transfected with the NFkB-dependent promoter together with increasing ratios of the CBP expres-
sion plasmid and subsequently pretreated with TGF-b1 before TNF-a stimulation to demonstrate that this effect is dose dependent. (C) Expression of
subdomains of CBP. The region of interaction between CBP and Smad2 was mapped to amino acids 1892–2175, and is shown schematically. Two sub-
domains of CBP corresponding to amino acids 1459–1891 or 1892–2441, respectively, were subcloned by PCR and expressed as epitope (Flag)-tagged
species and detected by anti-Flag immunoblot, as shown. (D) Overexpression of a specific subdomain of CBP can act as selective inhibitor of Smad-depen-
dent transcription when overexpressed. BAECs were transfected with either the TGF-b1 responsive reporter construct p3TP-lux (left), a Gal4-Smad2 fu-
sion protein expression construct together with a Gal4 reporter (middle), or a Gal4-Jun fusion protein expression construct together with the Gal4 re-
porter (right), and were stimulated by either soluble TGF-b1 (5 U/ml for 18 h) or coexpression of a constitutively active form of mitogen-activated
protein kinase kinase 1 (actMEKK1). The effect of overexpression of the subdomains of CBP described in the legend to Fig. 4 C was assessed by cotrans-
fecting these expression constructs as listed. Overexpression of the subdomain corresponding to the Smad interaction domain (1892–2441) was able to in-
hibit the TGF-b/Smad-dependent promoters but not the Gal4-Jun–mediated promoter. The adjacent subdomain of CBP (1459–1891) did not act as an
inhibitor of these promoters. (E) Overexpression of 1892 but not 1459 can reverse TGF-b1–mediated inhibition of NFkB-dependent transcription.
BAECs were cotransfected with the simplified NFkB-dependent promoter and the indicated subdomains of CBP (left). The cells were subsequently
stimulated with TNF-a with and without TGF-b1 pretreatment, as above. In the presence of the overexpressed 1892 subdomain of CBP, the TGF-b–
mediated inhibition of the NFkB-dependent promoter is not observed. The right panel shows cells that were transfected with the NFkB reporter and in-
creasing ratios of the 1892 subdomain expression vector, then pretreated with TGF-b1 before TNF-a stimulation, as above. Increasing doses of the 1892
expression vector result in a progressive decrease in the ability of TGF-b1 pretreatment to inhibit the cytokine induction of this promoter.702 Integration of TGF-b and Inflammatory Signaling via CBP in Endothelium
overexpression of 1892 completely abolished this inhibi-
tory effect. This effect was also dose dependent in that in-
creasing ratios of the 1892 subdomain expression vector re-
sulted in progressively less inhibition in response to TGF-b1
pretreatment (Fig. 4 E, right). This same pattern of re-
sponse was seen when the E-selectin promoter was used for
these experiments (data not shown). Taken together, these
results indicate that Smad–CBP interactions are required
for the inhibitory effects of TGF-b1 pretreatment on
NFkB-mediated gene expression, and that augmentation of
the effectively limited amount of CBP present in endothe-
lial cells is capable of reversing these effects.
Discussion
The ability of TGF-b1 to modulate inflammatory events
is thought to be one of the most critical actions of this cy-
tokine/growth factor in postnatal and adult mammals. In
this report, we have demonstrated that exogenous active
TGF-b1 can effectively inhibit the expression of the proin-
flammatory adhesion molecule E-selectin in cytokine-stim-
ulated endothelial cells both in vitro and in vivo. This ef-
fect occurs at the transcriptional level, as evidenced by
reporter gene experiments using the E-selectin promoter,
and is mediated by Smad proteins, as overexpression of spe-
cific inhibitory or dominant negative Smads can block
these actions. Furthermore, we are proposing that this inhi-
bition occurs as a result of a competition between Smad
proteins activated by TGF-b1 and NFkB proteins activated
by inflammatory cytokines for what appears to be a limited
amount of an essential transcriptional coactivator (CBP)
present in the nuclei of endothelial cells. This novel mech-
anism of action for TGF-b1 in endothelial cells is supported
by the following findings: (a) under conditions where
TGF-b1 pretreatment can effectively inhibit cytokine-
induced E-selectin expression in cultured endothelial cells,
the levels and state of activation of NFkB appear identical
to that seen with cytokine activation alone; (b) although
both p65 and Smad2 can be recruited to CBP-containing
complexes by either rhIL-1b or TGF-b1, respectively, only
Smad2 appears to be effectively recruited to CBP-contain-
ing complexes in the presence of both stimuli (i.e., TGF-b1
pretreatment); (c) augmentation (via overexpression) of
CBP levels in endothelial cells can effectively reverse TGF-
b1–mediated inhibition of cytokine-induced E-selectin ex-
pression in endothelial cells; and (d) selective inhibition of
Smad–CBP interactions via a dominant negative overex-
pression strategy effectively blocks TGF-b1–mediated inhi-
bition of E-selectin expression.
Although we have proposed a relatively simple model
involving a competition for limiting amounts of CBP, the
situation is likely to be more complex. Rather than a sim-
ple stoichiometric competition, there may be allosteric
changes in the conformation of CBP that are induced by
Smad binding and inhibit its ability to interact with NFkB.
In addition, there are several additional classes of transcrip-
tional coactivators and corepressors in most cells, and these
may be playing a role (32). To investigate this possibility,
we have examined the effects of overexpression of p300/
CBP-associated factor 1 and steroid receptor coactivator 1,
and have not observed any modulation of the effects of
TGF-b1 in endothelial cells (data not shown). Thus, in gen-
eral, it is not yet clear what determines which transcription
factors are successful in recruiting CBP, or why other tran-
scriptional complexes are not (30). In our hands, the ability
of TGF-b1 pretreatment to effectively inhibit NFkB-medi-
ated E-selectin gene expression could be seen with as little
as 30 min of pretreatment with TGF-b1, suggesting that
significant alterations in the phenotype of the endothelial
cells were not being induced. In addition, because we did
not find any evidence that p65 and Smad2 were in the same
transcriptional complexes in endothelial cells, it is unlikely
that Smad-mediated recruitment of a corepressor to the
E-selectin promoter is occurring. Thus, the simplest model
that is consistent with the data presented is one where the
limited amount of the required coactivator, CBP, present
in endothelial cells is selectively recruited to Smad protein–
containing complexes, and thus is not available to interact
with NFkB even though the latter has been activated. This
type of coactivator-mediated signal integration, or “coacti-
vator competition,” has been demonstrated in other sys-
tems. For example, the antagonistic interactions between
IFN-regulated signal transducer and activator of transcrip-
tion proteins and the activating protein 1 (AP-1) family of
transcriptional activators in macrophages has been postu-
lated to be due to this type of coactivator competition (28).
In endothelial cells, the antiinflammatory actions of gluco-
corticoids may be due to an analogous process involving
steroid receptors and NFkB (33). In addition, p53 and
NFkB have been reported to mutually repress each other’s
ability to stimulate transcription by an analogous mecha-
nism involving coactivator competition (34).
Previous work has demonstrated that TGF-b1 can inhibit
B cell activation via stabilization and/or induction of IkB,
the inhibitory subunit of NFkB (35). Our results in vascu-
lar endothelium indicate that the antiinflammatory actions
of this growth factor on endothelium are due, at least in
part, to a distinct mechanism of action. Under conditions
where TGF-b1 pretreatment effectively inhibited cytokine-
induced E-selectin expression, we found that IkB levels
were markedly diminished, and NFkB activation (as as-
sessed by DNA binding assay) was preserved. Furthermore,
our data indicate that TGF-b1–mediated inhibition of in-
flammatory E-selectin expression can occur in vascular en-
dothelium in vivo. As the data in Fig. 3 indicate, pretreat-
ment of rats with systemic TGF-b1 before LPS challenge
can effectively block the induction of E-selectin mRNA in
multiple tissues. This effect must be occurring in the vascu-
lar endothelium, as this is the only cell type present within
these tissues that express this gene (1). In this setting, the
activation of NFkB as assessed by gel shift analysis of tissue
extracts appears to be preserved.
We assessed the specificity of this effect by specifically
interfering with defined Smad–coactivator (CBP) interac-
tions via a dominant negative strategy. By overexpressing a
subdomain of CBP that is known to mediate the interac-703 DiChiara et al.
tions between this coactivator and Smad2 and -4, we can
demonstrate a specific and selective inhibition of Smad-
mediated transcriptional events. Under these conditions,
TGF-b1 pretreatment of endothelial cells does not inhibit
NFkB-mediated gene expression. These results not only
demonstrate the requirement for Smad–coactivator interac-
tions in the inhibitory process, but also suggest a novel level
at which the actions of these growth factors may be modu-
lated. Reagents designed to specifically interfere with de-
fined transcription factor–coactivator interactions may al-
low one to selectively modulate the actions of these growth
factors at the level of the nucleus.
The recent elucidation of the detailed molecular events
by which TGF-b1 and related cytokines/growth factors
elicit their cellular effects has resulted in the realization that
these pathways can functionally interact with a variety of
other intracellular signaling pathways in cells (7). We have
demonstrated that TGF-b1 can functionally interact with
the NFkB signaling pathway in endothelial cells by a
mechanism involving nuclear coactivator interactions. Be-
cause the coactivators CBP/P300 interact with a wide vari-
ety of transcriptional effectors that are the targets of diverse
signaling pathways, these observations may begin to pro-
vide a conceptual framework for understanding the com-
plex molecular interactions underlying the pleiotropic, or
“context-specific,” actions of this class of cytokines/growth
factors.
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